The administration of proton pump inhibitors with the CDK4/6 inhibitor abemaciclib does not affect the clinical outcome of metastatic breast cancer patients
质子泵抑制剂与 CDK4/6 抑制剂阿贝西利联合用药不会影响转移性乳腺癌患者的临床结局。
期刊:Therapeutic Advances in Drug Safety
影响因子:3.4
doi:10.1177/20420986251414591
Crucitta, Stefania; Cinacchi, Paola; Bargagna, Irene; Biondani, Pamela; Giontella, Elena; Palleschi, Michela; Omarini, Claudia; Belluzzi, Lorenzo; Angelini, Lucia; Meattini, Icro; Visani, Luca; Stucci, Stefania; Porta, Camillo; Fontana, Andrea; De Giorgi, Ugo; Fogli, Stefano; Danesi, Romano; Del Re, Marzia
